Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Leber’s hereditary optic neuropathy (LHON) is a mitochondrially inherited disease leading to blindness. A mitochondrial DNA point mutation at the 11778 nucleotide site of the NADH dehydrogenase subunit 4 ( ND4 ) gene is the most common cause. The aim of this study was to evaluate the efficacy and safety of a recombinant adeno-associated virus 2 (AAV2) carrying ND4 (rAAV2-ND4) in LHON patients carrying the G11778A mutation. Nine patients were administered rAAV2-ND4 by intravitreal injection to one eye and then followed for 9 months. Ophthalmologic examinations of visual acuity, visual field and optical coherence tomography were performed. Physical examinations included routine blood and urine. The visual acuity of the injected eyes of six patients improved by at least 0.3 log MAR after 9 months of follow-up. In these six patients, the visual field was enlarged but the retinal nerve fibre layer remained relatively stable. No other outcome measure was significantly changed. None of the nine patients had local or systemic adverse events related to the vector during the 9-month follow-up period. These findings support the feasible use of gene therapy for LHON.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Different trials have demonstrated the safety and efficacy of gene therapy using an AAV vector, delivered through an intravitreal route, for LHON.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two similar gene therapy programmes led by groups in the USA25,26 and China,27–30 have targeted the m.11778G>A mutation in MT-ND4, also using a viral vector containing a cDNA coding the human wild-type mitochondrial ND4 protein.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Mitochondrial dysfunction as a cause of optic neuropathies
Carelli, V., Ross-Cisneros, F. N., & Sadun, A. A. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.10.003 · Cited by 839
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Mackey, D. A., Oostra, R., Rosenberg, T., Nikoskelainen, E. K., Brontë-Stewart, J., Poulton, J., Harding, A. E., Govan, G. G., Bolhuis, P. A., & Nørby, S. (1996) · PubMed Central · Cited by 339
Ueber hereditäre und congenital-angelegte Sehnervenleiden
Leber, T. (1871) · Albrecht von Græfe's Archiv für Ophthalmologie · doi:10.1007/bf01694557 · Cited by 272
Oestrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy
Giordano, C., Montopoli, M., Perli, E., Orlandi, M., Fantin, M., Ross-Cisneros, F. N., Caparrotta, L., Martinuzzi, A., Ragazzi, E., Ghelli, A., et al. (2011) · Brain · doi:10.1093/brain/awq276 · Cited by 252
Idebenone Treatment In Leber's Hereditary Optic Neuropathy
Carelli, V., La Morgia, C., Valentino, M. L., Rizzo, G., Carbonelli, M., De Negri, A. M., Sadun, F., Carta, A., Guerriero, S., Simonelli, F., et al. (2011) · Brain · doi:10.1093/brain/awr180 · Cited by 241
Research works printed but not linked: 2
- Pei, H., Wan, X., Hu, W., Dong, X. & Li, B. Constructing and detecting a new rAAV2/2-ND4. Eye Science 28, 55–59 (2013).
- Gao, J. et al. Comparison of immunosuppressive effects and ND4 expression among different immunosuppressive strategies following AAV2-ND4 gene treatment for Leber hereditary optic neuropathy. J. Huazhong Acta Med. Univ. Sci. Tech. 42, 187–191 (2013).
Cited by
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“Wan et al.161 evaluated the safety and efficacy of an AAV2 vector encoding for mitochondrial reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase 4 gene (ND4) administered to the vitreous in nine Leber’s hereditary optic neuropathy (LHON) patients (ClinicalTrials.gov: NCT01267422).”
BackgroundDias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Mitochondrial medicine in the omics era
Rahman, J., & Rahman, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30727-x · Cited by 283
“A recent preliminary report demonstrated safety and suggested efficacy of rAAV2-ND4 therapy.(133) Gene therapy for nuclear-encoded mitochondrial disorders Gene therapy involves the correction of a genetic abnormality by delivering a ‘correct’ copy of the affected gene to cells using a vector.”
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Gene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
“Leber’s hereditary optic neuropathy (LHON), characterized by rapid loss of vi ‐ sion, is caused by a mutation in the NADH dehydrogenase protein subunit 4 (ND4) [278].”
Mitochondrial function in development and disease
Rossmann, M. P., Dubois, S. M., Agarwal, S., & Zon, L. I. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048912 · Cited by 184
“, 2014), this gene therapy is currently pursued in human clinical trials by three investigator groups (Guy et al., 2017; Wan et al., 2016; Yu-Wai-Man et al., 2020; Yuan et al., 2020).”
BackgroundNewman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
Emerging therapies for mitochondrial diseases
Hirano, M., Emmanuele, V., & Quinzii, C. M. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170114 · Cited by 162
Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139
“Details of the experimental design and methodology have been previously published (Wan et al., 2016) and are briefly described below.”
BackgroundMethodInfluentialSelf-citationGene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Boia, R., Ruzafa, N., Aires, I. D., Pereiro, X., Ambrósio, A. F., Vecino, E., & Santiago, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072262 · Cited by 138
Gene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Diagnosis and clinical features of common optic neuropathies
Biousse, V., & Newman, N. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30237-x · Cited by 138
Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward
Bennett, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.008 · Cited by 109
Bouquet, C., Vignal Clermont, C., Galy, A., Fitoussi, S., Blouin, L., Munk, M. R., Valero, S., Meunier, S., Katz, B., Sahel, J. A., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6902 · Cited by 104
“(%) of patients 0 2 (20) 6 (60) 2 (20) 10 (100) No.”
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 107
“In contrast to other gene augmentation therapies, a strategy involving the allotopic expression of the ND4 gene (expression of a mitochondrial gene transferred to the nucleus) was employed in ongoing clinical trials to rescue the mitochondrial respiratory chain defect in LHON patients (Feuer et al., 2016; Wan et al.,…”
InfluentialNewman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Drug Development for the Therapy of Mitochondrial Diseases
Weissig, V. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.002 · Cited by 97
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 97
“an associated visual field enlargement [97].”
Mammadzada, P., Corredoira, P. M. F., & André, H. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03422-9 · Cited by 99
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies
Sanchez, M. I. G. L., Crowston, J. G., Mackey, D. A., & Trounce, I. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.004 · Cited by 90
Zeviani, M., & Carelli, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010210 · Cited by 95
Bottani, E., Lamperti, C., Prigione, A., Tiranti, V., Persico, N., & Brunetti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111083 · Cited by 94
“reported the amelioration of visual acuity in the injected eyes [371].”
BackgroundInfluentialOcular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
Leber hereditary optic neuropathy: bridging the translational gap
Jurkutė, N., & Yu‐Wai‐Man, P. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000410 · Cited by 75
Human Mitochondrial DNA: Particularities and Diseases
Habbane, M., Montoya, J., Rhouda, T., Sbaoui, Y., Radallah, D., & Emperador, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101364 · Cited by 87
Britten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Chun, B. Y., & Rizzo, J. F. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.06.001 · Cited by 67
Mitochondrially-targeted treatment strategies
Bozi, L. H. M., Campos, J. C., Zambelli, V. O., Ferreira, N. D., & Ferreira, J. C. B. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100836 · Cited by 70
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 65
“Preliminary findings showed that eyes tolerated the transplant, and cellular adaptive optics OCT imaging suggested incorporation of the transplanted cells into the macula [Park et al., 2015].”
InfluentialHafler, B. P. (2016) · Retina · doi:10.1097/iae.0000000000001341 · Cited by 67
Towards a therapy for mitochondrial disease: an update
Garone, C., & Viscomi, C. F. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180134 · Cited by 68
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 61
“Neuropathy due to the G11778A ND4 mitochondrial mutation.(62,63) Preliminary data from the Phase I/II trial showed promising results (NCT02064569) and provided the foundation for two Phase III clinical trials which are currently underway (NCT02652780, NCT02652767).”
BackgroundMitochondrial functions and rare diseases
Dard, L., Blanchard, W., Hubert, C., Lacombe, D., & Rossignol, R. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100842 · Cited by 68
Nutritional Optic Neuropathies: State of the Art and Emerging Evidences
Roda, M., di Geronimo, N., Pellegrini, M., & Schiavi, C. (2020) · Nutrients · doi:10.3390/nu12092653 · Cited by 69
Strategies for fighting mitochondrial diseases
Viscomi, C. F., & Zeviani, M. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13046 · Cited by 66
The Security of Medical Data on Internet Based on Differential Privacy Technology
Lv, Z., & Piccialli, F. (2020) · ACM Transactions on Internet Technology · doi:10.1145/3382769 · Cited by 64
A Review of Mitochondrial Optic Neuropathies: From Inherited to Acquired Forms
Pilz, Y. L., Bass, S. J., & Sherman, J. (2016) · Journal of Optometry · doi:10.1016/j.optom.2016.09.003 · Cited by 58
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant
Boominathan, A., Vanhoozer, S., Basisty, N., Powers, K., Crampton, A. L., Wang, X., Friedricks, N., Schilling, B., Brand, M. D., & O'Connor, M. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw756 · Cited by 27
Protecting retinal ganglion cells
Khatib, T. Z., & Martin, K. R. G. (2017) · Eye · doi:10.1038/eye.2016.299 · Cited by 53
Update on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
Mitochondrial optic neuropathies
Carelli, V., Morgia, C. L., & Yu‐Wai‐Man, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00010-5 · Cited by 55
Lu, H., Wang, X., Li, M., Ji, D., Liang, D., Liang, C., Liu, Y., Zhang, Z., Cao, Y., & Zou, W. (2022) · Cells · doi:10.3390/cells12010020 · Cited by 51
Ratican, S., Osborne, A., & Martin, K. R. G. (2018) · Neural Plasticity · doi:10.1155/2018/7108948 · Cited by 49
“[96] carried out at Tongji Hospital in Wuhan, China, evaluated the safety and efficacy of AAV2-mediated allotropic expression of ND4 in nine patients with the G11778A mutation.”
BackgroundResultInfluentialAn overview of development in gene therapeutics in China
Wang, D., Wang, K., & Cai, Y. (2020) · Gene Therapy · doi:10.1038/s41434-020-0163-7 · Cited by 45
“Though have shown the safety and efficacy in numerous clinical trials [60, 61], the vector has recently been suspected linking to cancers [62, 63], still informing us to be cautious regarding the long-term safety of AAV.”
BackgroundSelf-citationJurkutė, N., Majander, A. S., Bowman, R. J. C., Votruba, M., Abbs, S. J., Acheson, J. F., Lenaers, G., Amati‐Bonneau, P., Moosajee, M., Arno, G., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0235-y · Cited by 42
Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Mishra, A., Vijayasarathy, C., Cukras, C. A., Wiley, H. E., Sen, H. N., Zeng, Y., Wei, L. L., & Sieving, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.013 · Cited by 38
Current advances in gene therapy of mitochondrial diseases
Soldatov, V. O., Kubekina, M. V., Skorkina, M. Y., Белых, А. Е., Egorova, T. V., Корокин, М. В., Pokrovskiy, M. V., Deykin, A. V., & Angelova, P. R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03685-0 · Cited by 47
Developments in the Treatment of Leber Hereditary Optic Neuropathy
Chen, B. S., Yu‐Wai‐Man, P., & Newman, N. J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01246-y · Cited by 44
Mitochondria and the eye—manifestations of mitochondrial diseases and their management
Chen, B. S., Harvey, J. P., Gilhooley, M. J., Jurkutė, N., & Yu‐Wai‐Man, P. (2023) · Eye · doi:10.1038/s41433-023-02523-x · Cited by 51
Targeting mitochondrial function to treat optic neuropathy
Gueven, N., Nadikudi, M., Daniel, A., & Chhetri, J. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.07.013 · Cited by 41
Treatment strategies for Leber hereditary optic neuropathy
Jurkute, N., Harvey, J., & Yu-Wai-Man, P. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000646 · Cited by 38
Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice
Jolly, J. K., Bridge, H., & MacLaren, R. E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01076 · Cited by 38
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37
Correction of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J. D., Justus, S., Cabral, T., & Tsang, S. H. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 41
“NCT01267422 Bin Li – Intravitreal rAAV2-ND4 [59]”
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 38
Coutinho, E., Batista, C., de Sousa, F. P., Queiroz, J. A., & Costa, D. R. B. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00823 · Cited by 39
Фу, Л., Kwok, S. S., Chan, Y. K., Lai, J. S. M., Pan, W., Nie, L., & Shih, K. C. (2019) · BioMed Research International · doi:10.1155/2019/8397521 · Cited by 37
“-ese clinical trials showed encouraging preliminary results with improvement of visual function [106, 107].”
BackgroundVoretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness
Patel, U. A., Boucher, M., de Léséleuc, L., & Visintini, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 34
Duong, T. T., Lim, J., Vasireddy, V., Papp, T., Nguyen, H., Leo, L., Pan, J., Zhou, S., Chen, H. I., Bennett, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/7281912 · Cited by 33
“Although AAV serotype 2 (AAV2) is the most studied with respect to safety and efficacy and is the first AAV vector approved as a drug for the treatment of a retinal disease, other AAV serotypes have great potential and their utility needs to be fully elucidated [1, 2, 10, 11].”
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Theodorou-Kanakari, A., Karampitianis, S., Karageorgou, V., Kampourelli, E., Kapasakis, E., THEODOSSIADIS, P. G., & Chatziralli, I. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0776-z · Cited by 35
Zhang, Y., Li, X., Yuan, J., Tian, Z., Liu, H., Wang, D., & Li, B. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13515 · Cited by 32
Self-citationFive-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
Yu‐Wai‐Man, P., Newman, N. J., Biousse, V., Carelli, V., Moster, M. L., Vignal‐Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5375 · Cited by 41
Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance
Kuo, C., & Liu, C. J.-L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111884 · Cited by 37
“Clinical trials conducted on patients with congenital retinal diseases such as Leber hereditary optic neuropathy have shown promising results with direct gene medical application in the treatment of optic neuropathy [124,125].”
BackgroundTreatment of Leber’s hereditary optic neuropathy: An overview of recent developments
Zuccarelli, M., Vella-Szijj, J., Serracino‐Inglott, A., & Borg, J.-J. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120936592 · Cited by 33
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 31
Leber’s hereditary optic neuropathy: Update on current diagnosis and treatment
Esmaeil, A., Ali, A., & Behbehani, R. S. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1077395 · Cited by 38
“3 logMAR after a period of nine months (85).”
BackgroundGene therapy in optic nerve disease
DeBusk, A. A., & Moster, M. L. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000473 · Cited by 28
“[12], enrolled nine patients in a prospective study where the eye with the worse visual acuity was injected with a single dose of rAAV2-ND4.”
BackgroundVIGNAL-CLERMONT, C., YU-WAI-MAN, P., NEWMAN, N. J., CARELLI, V., MOSTER, M. L., BIOUSSE, V., SUBRAMANIAN, P. S., WANG, A.-G., DONAHUE, S. P., LEROY, B. P., et al. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.11.026 · Cited by 25
Current and Future Landscape in Genetic Therapies for Leber Hereditary Optic Neuropathy
Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2023) · Cells · doi:10.3390/cells12152013 · Cited by 29
“In these six patients, the VF was enlarged, but the RNFL remained relatively stable [41].”
BackgroundThe Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy
Zhang, Y., Tian, Z., Yuan, J., Liu, C. X., Liu, H. L., Qi, S., & Li, B. (2018) · Current Gene Therapy · doi:10.2174/1566523218666171129204926 · Cited by 25
Self-citationCao, X., Yung, J., Mak, H., & Leung, C. K. S. (2019) · Gene Therapy · doi:10.1038/s41434-019-0060-0 · Cited by 20
Ford, J. L., Karatza, E., Mody, H. R., Shastri, P. N., Khajehpour, S., Yang, T., Swanson, M., Chao, D. L., & Devineni, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3230 · Cited by 25
“Although some earlier retina gene therapy clinical trials excluded patients with pre-existing AAV antibodies, such as for rAAV2-ND4 administered via IVT to patients with Leber hereditary optic neuropathy, 50 this is no longer common practice.”
BackgroundEvaluation of Leber's hereditary optic neuropathy patients prior to a gene therapy clinical trial
Yang, S., Yang, H., Ma, S., Wang, S., He, H., Zhao, M.-J., & Li, B. (2016) · Medicine · doi:10.1097/md.0000000000005110 · Cited by 22
Self-citationLeber’s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development
Karaarslan, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01113-2 · Cited by 21
Newman, N. J., Biousse, V., Yu‐Wai‐Man, P., Carelli, V., Vignal‐Clermont, C., Montestruc, F., Taiel, M., & Sahel, J. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.10.002 · Cited by 22
Treatment for mitochondrial diseases
Liufu, T., & Wang, Z.-X. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0034 · Cited by 21
“…G11778A mutation according to three studies (one double-blind, randomized, sham-controlled, two open-label studies) (Guy et al. 2017; Nancy 2020; Wan et al. 2016) using viral vector carrying the nuclear encoded ND4 with mitochondrial targeting sequences to relieve the visual defect of patients…”
MethodVisual field variability after gene therapy for Leber’s hereditary optic neuropathy
Yuan, J.-J., Zhang, Y., Wang, L.-L., Cheng, M.-S., Ma, S.-Q., Gao, Q., & Li, B. (2018) · Ophthalmic Research · doi:10.1159/000487485 · Cited by 17
Self-citationThe Present and Future of Mitochondrial-Based Therapeutics for Eye Disease
Ji, M. H., Kreymerman, A., Belle, K. C., Ghiam, B. K., Muscat, S. P., Mahajan, V. B., Enns, G. M., Mercola, M. A., & Wood, E. H. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.4 · Cited by 20
Neuroimaging in Leber Hereditary Optic Neuropathy: State-of-the-art and future prospects
Chow-Wing-Bom, H. T., Callaghan, M. F., Wang, J., Wei, S., Dick, F., Yu‐Wai‐Man, P., & Dekker, T. M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103240 · Cited by 18
McGrady, N. R., Boal, A. M., Risner, M. L., Taiel, M., Sahel, J., & Calkins, D. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.035 · Cited by 18
CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING
Cho, G. Y., Schaefer, K. A., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2018) · Retina · doi:10.1097/iae.0000000000002197 · Cited by 16
What Is New in Glaucoma: From Treatment to Biological Perspectives
Nuzzi, R., Marolo, P., & Nuzzi, A. (2021) · Journal of Ophthalmology · doi:10.1155/2021/5013529 · Cited by 17
“Concerning LHON, it has been shown that intravitreal injections of AAV2-ND4 (adeno-associated viruses type 2 carrying NADH dehydrogenase, subunit 4 gene) viral vector are safe and feasible [79].”
Autophagy in white matter disorders of the CNS : mechanisms and therapeutic opportunities
Nutma, E., Marzin, M. C., Cillessen, S. A. G. M., & Amor, S. (2020) · The Journal of Pathology · doi:10.1002/path.5576 · Cited by 16
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 22
Radelfahr, F., & Klopstock, T. (2019) · Der Nervenarzt · doi:10.1007/s00115-018-0666-2 · Cited by 16
Kurimoto, T., Ueda, K., Mori, S., Kamada, S., Sakamoto, M., Yamada‐Nakanishi, Y., Matsumiya, W., & Nakamura, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051359 · Cited by 13
“reported that a single-dose intravitreal injection of rAAV2-ND4 in nine cases of LHON with the 11,778 mtDNA mutation resulted in the logMAR visual acuity improving by >3 lines in six cases over a nine-month period [25].”
BackgroundThe Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics
Saravanan, S., Lewis, C. J., Dixit, B., O’Connor, M. S., Stolzing, A., & Boominathan, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020490 · Cited by 13
Current progress in the therapeutic options for mitochondrial disorders.
Koňaříková, E., Markovic, A., Korandová, Z., Houštěk, J., & Mráček, T. (2020) · Physiological Research · doi:10.33549/physiolres.934529 · Cited by 16
Gene therapy for the mitochondrial genome: Purging mutations, pacifying ailments
Siva, A., Mahalakshmi, R., Bhakta-Guha, D., & Guha, G. (2018) · Mitochondrion · doi:10.1016/j.mito.2018.06.002 · Cited by 13
From Bench to Bedside—Delivering Gene Therapy for Leber Hereditary Optic Neuropathy
Chen, B. S., & Yu‐Wai‐Man, P. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041282 · Cited by 14
Gene therapy for glaucoma: Targeting key mechanisms
Henderson, J., O’Callaghan, J., & Campbell, M. (2024) · Vision Research · doi:10.1016/j.visres.2024.108502 · Cited by 12
“…a gene therapy for Leber ’ s congenital optic neuropathy that utilises a recombinant AAV2/2 vector injected intravitreally to deliver a human wild-type ND4 transgene to RGCs, while generally safe, has shown only marginal benefit (Wan et al., 2016; Guy et al., 2017; Newman et al., 2022).”
Clinical trials in Leber hereditary optic neuropathy: outcomes and opportunities
Chen, B. S., & Newman, N. J. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001343 · Cited by 12
Liu, H., Yuan, J., Tian, Z., Li, X., Song, L., & Li, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025307 · Cited by 11
“Visual field examination is an important procedure for diagnosis, gene therapy, evaluation of treatment efficacy and follow-up observation in patients with LHON.”
BackgroundMethodSelf-citationStephenson, K. A. J., McAndrew, J., Kenna, P. F., & Cassidy, L. (2022) · Neuro-Ophthalmology · doi:10.1080/01658107.2022.2032761 · Cited by 11
“Human intravitreal gene therapy trials have shown 15-letter gains in 66%, with effects from monocular injection seen bilaterally.(55,56) A 15letter improvement from a baseline of logMAR 1.”
Background
Metadata
- Authors
- Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., Wang, D.-W., & Li, B.
- Affiliations
- Tongji Hospital (CN)
- Ezhou Central Hospital (CN)
- Sun Yat-sen University (CN)
- Corresponding author
- Li, Bin
- Venue
- Scientific Reports
- Published
- 2016-02-19
- Volume
- 6
- Issue
- 1
- Pages
- 21587-21587
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4759604
- OpenAlex
- W2397855699
- Cited by
- 182
- References
- 31
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 16 · 2022: 21 · 2021: 19 · 2020: 19 · 2019: 21 · 2018: 21 · 2017: 17 · 2016: 13
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (30872823, 30801260, 2010021, 81271015)
- Tongji University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- Leber's hereditary optic neuropathy, NADH dehydrogenase subunit 4, mitochondrial DNA mutations, intravitreal injection, visual acuity, visual field, retinal nerve fiber layer, treatment safety, mitochondrial disease
- MeSH terms
- Dependovirus, Administration, Oral, Adolescent, Adult, Child, Electroretinography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, NADH Dehydrogenase, Plasmids, Prednisolone, Genetic Therapy, Treatment Outcome, Point Mutation, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Young Adult, HEK293 Cells, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.